Precision BioSciences
- Country
- 🇺🇸United States
- Ownership
- -
- Employees
- 109
- Market Cap
- $70.2M
- Introduction
Precision BioSciences, Inc. is a biotechnology company, which engages in the development of genome editing technologies. It operates through the Therapeutics and Food segments. The Therapeutics segment focuses on the development of products in the field of immuno-oncology and of novel products outside immuno-oncology to treat human diseases. The Food segment applies ARCUS, the company's proprietary genome editing platform, to develop food and nutrition products through collaboration agreements with consumer-facing companies. The company was founded by Derek N. Jantz, Jeff Smith, and Matthew R. Kane on January 26, 2006 and is headquartered in Durham, NC.
CAR T-cell Therapy Pipeline Surges with 180+ Companies Advancing Novel Cancer Treatments
The CAR T-cell therapy pipeline has experienced significant growth, with over 180 companies actively developing more than 200 innovative cell therapy candidates across various stages of clinical development.
TG Therapeutics Partners with MaxCyte to Advance Novel CAR T-Cell Therapy for Progressive MS
TG Therapeutics has secured access to MaxCyte's flow electroporation technology to develop azercabtagene zapreleucel, an off-the-shelf CAR T-cell therapy for progressive multiple sclerosis.
iECURE's Gene Insertion Therapy ECUR-506 Shows Complete Clinical Response in OTC Deficiency Trial
iECURE's ECUR-506, an in vivo gene insertion therapy, demonstrated a complete clinical response in an infant with neonatal-onset Ornithine Transcarbamylase (OTC) deficiency.
Precision BioSciences' PBGENE-HBV Shows Promise in Phase 1 Hepatitis B Trial
Precision BioSciences' PBGENE-HBV demonstrated a favorable safety profile in initial Phase 1 trial results, with no serious adverse events reported in the first cohort.
Precision BioSciences' HBV Gene Editing Trial Approved in Moldova
Precision BioSciences received approval in Moldova for a clinical trial of PBGENE-HBV, an in vivo gene editing therapy targeting chronic hepatitis B.
Merck Licenses Cancer Drug from LaNova, Tune Therapeutics Advances HBV Therapy, and Amgen Defends Obesity Drug
• Merck will license a new cancer drug from LaNova Medicines for $588 million upfront, potentially reaching $2.7 billion in milestone payments, to bolster its oncology portfolio. • Tune Therapeutics is set to initiate human trials in New Zealand for its epigenetic editing therapy targeting hepatitis B virus (HBV), following regulatory clearance. • Amgen defended its obesity drug candidate, MariTide, addressing concerns about bone mineral density loss based on preliminary, non-finalized data from early trials.
Precision BioSciences Advances PBGENE-HBV to Phase 1 Trial for Chronic Hepatitis B Treatment
Precision BioSciences received approval for its Clinical Trial Application for PBGENE-HBV, a gene editing therapy for chronic hepatitis B.
Precision BioSciences' PBGENE-HBV Receives Clearance for Phase 1 Trial in Chronic Hepatitis B
Precision BioSciences has received CTA approval in Moldova to begin a Phase 1 clinical trial of PBGENE-HBV, a gene editing therapy for chronic hepatitis B.
Precision BioSciences' PBGENE-HBV Receives First Clinical Trial Approval for Chronic Hepatitis B Treatment
Precision BioSciences has received CTA approval in Moldova for PBGENE-HBV, the first in vivo gene editing program for chronic hepatitis B to enter clinical trials.
Precision BioSciences' PBGENE-HBV Receives Approval for Phase 1 Trial in Chronic Hepatitis B
Precision BioSciences has received CTA approval in Moldova to begin a Phase 1 clinical trial of PBGENE-HBV for chronic hepatitis B treatment.